Centessa Pharmaceuticals Plc Quick Ratio (CNTA) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Centessa Pharmaceuticals Plc  (NASDAQ: CNTA)

Centessa Pharmaceuticals Plc's Quick Ratio

CNTA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Centessa Pharmaceuticals Plc's Cash & cash equivalent, this led to improvement in Centessa Pharmaceuticals Plc's Quick Ratio to 7.56, Quick Ratio remained below Centessa Pharmaceuticals Plc average.

Within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Quick Ratio than Centessa Pharmaceuticals Plc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 0 to 458.

Explain Quick Ratio?
How much Cash & cash equivalents CNTA´s has?
What are CNTA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CNTA Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 51.12 % -25.97 % 10.29 % 10.98 % -11.78 %
Y / Y Cash & cash equivalent Change -2.78 % -38.91 % -52.51 % -14.96 % 23.6 %
Quick Ratio MRQ 7.56 6.86 8.45 8.44 11.76
CNTA's Total Ranking # 458 # 0 # 291 # 304 # 272
Seq. Current Liabilities Change -14.82 % 47.43 % -1.93 % 22.69 % -58.27 %
Seq. Cash & cash equivalent Change -6.11 % 19.64 % -1.8 % -11.87 % -41 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 209
Overall Market # 458


Quick Ratio Statistics
High Average Low
25.38 12.57 6.51
(Jun 30 2021)   (Dec 31 2023)




Financial Statements
Centessa Pharmaceuticals Plc's Current Liabilities $ 37 Millions Visit CNTA's Balance sheet
Centessa Pharmaceuticals Plc's Cash & cash equivalent $ 277 Millions Visit CNTA's Balance sheet
Source of CNTA's Sales Visit CNTA's Sales by Geography


Cumulative Centessa Pharmaceuticals Plc's Quick Ratio

CNTA's Quick Ratio for the trailling 12 Months

CNTA Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 2.19 % -9.12 % 15.03 % 5.46 % -2.09 %
Y / Y Cash & cash equivalent TTM Growth -32.4 % -29.47 % -2.8 % 44.5 % 47.43 %
Quick Ratio TTM 7.72 8.54 8.96 11.11 11.67
Total Ranking TTM # 2805 # 0 # 2164 # 2395 # 2177
Seq. Current Liabilities TTM Growth 9.82 % -10.68 % 1.96 % 2.17 % -2.33 %
Seq. Cash & cash equivalent TTM Growth -0.74 % -14.85 % -17.73 % -2.79 % 3.56 %

Quick ratio ranking by company, industry and sector >> Back to CNTA Financial Strength Comparisons >> Go to Compare CNTA Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q1 2026 to $36.57 millions, cumulative Quick Ratio decreased to 7.72 below the Centessa Pharmaceuticals Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 394 other companies have achieved higher Quick Ratio than Centessa Pharmaceuticals Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 0 to 2805.

Explain Quick Ratio?
How much Cash & cash equivalents CNTA´s has?
What are CNTA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 395
Healthcare Sector # 797
Within the Market # 2805


trailing twelve months Quick Ratio Statistics
High Average Low
22.18 11.89 7.72
(Mar 31 2022)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Generate Biomedicines Inc   20.78 $ 516.641  Millions$ 24.861  Millions
Stoke Therapeutics Inc   20.32 $ 343.545  Millions$ 16.905  Millions
Liquidia Corporation  20.29 $ 222.786  Millions$ 10.981  Millions
Vyne Therapeutics Inc   20.17 $ 24.928  Millions$ 1.236  Millions
Alto Neuroscience Inc   20.11 $ 263.762  Millions$ 13.115  Millions
Evommune Inc   19.94 $ 211.464  Millions$ 10.603  Millions
Tyra Biosciences Inc   19.91 $ 383.466  Millions$ 19.256  Millions
Sagimet Biosciences inc   19.88 $ 104.539  Millions$ 5.258  Millions
Corvus Pharmaceuticals Inc   19.55 $ 236.714  Millions$ 12.110  Millions
Ligand Pharmaceuticals Incorporated  19.17 $ 779.405  Millions$ 40.667  Millions
Dyne Therapeutics Inc   18.97 $ 972.156  Millions$ 51.249  Millions
Agios Pharmaceuticals Inc   18.41 $ 737.038  Millions$ 40.040  Millions
Crinetics Pharmaceuticals Inc   18.17 $ 1,291.306  Millions$ 71.086  Millions
Relmada Therapeutics Inc  18.15 $ 233.963  Millions$ 12.892  Millions
Phio Pharmaceuticals Corp  17.93 $ 17.031  Millions$ 0.950  Millions
Amylyx Pharmaceuticals Inc   17.52 $ 279.768  Millions$ 15.966  Millions
Minerva Neurosciences Inc   17.42 $ 78.065  Millions$ 4.482  Millions
Lexicon Pharmaceuticals Inc   17.24 $ 170.658  Millions$ 9.898  Millions
Sellas Life Sciences Group Inc   16.60 $ 107.197  Millions$ 6.456  Millions
Pliant Therapeutics Inc   16.50 $ 170.892  Millions$ 10.359  Millions
Innoviva Inc   16.50 $ 603.085  Millions$ 36.558  Millions
Dianthus Therapeutics Inc   16.29 $ 617.109  Millions$ 37.884  Millions
Janux Therapeutics Inc   16.23 $ 956.386  Millions$ 58.915  Millions
Praxis Precision Medicines Inc   16.12 $ 786.865  Millions$ 48.806  Millions
Nuvalent Inc   15.88 $ 1,287.476  Millions$ 81.051  Millions
Oric Pharmaceuticals Inc   15.86 $ 281.932  Millions$ 17.771  Millions
Adc Therapeutics Sa  15.86 $ 231.008  Millions$ 14.567  Millions
Protagonist Therapeutics inc   15.86 $ 547.786  Millions$ 34.549  Millions
Aprea Therapeutics Inc   15.80 $ 46.466  Millions$ 2.941  Millions
Emmis Acquisition Corp   15.64 $ 0.782  Millions$ 0.050  Millions

Date modified: 2026-10-05T11:03:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.